In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor
- 1 November 2018
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (20) , 3404-3408
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors2015
- Recent advances of p53-MDM2 small molecule inhibitors (2011-present).Current Medicinal Chemistry, 2015
- Drugging the p53 pathway: understanding the route to clinical efficacyNature Reviews Drug Discovery, 2014
- Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Current Medicinal Chemistry, 2014
- MDM2, MDMX and p53 in oncogenesis and cancer therapyNature Reviews Cancer, 2013
- The central valine concept provides an entry in a new class of non peptide inhibitors of the p53–MDM2 interactionBioorganic & Medicinal Chemistry Letters, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Metabolic Soft Spot Identification and Compound Optimization in Early Discovery Phases Using MetaSite and LC-MS/MS ValidationJournal of Medicinal Chemistry, 2008
- Discovery of Potent Antagonists of the Interaction between Human Double Minute 2 and Tumor Suppressor p53Journal of Medicinal Chemistry, 2000
- Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation DomainScience, 1996